ENTITY
Fosun Pharma

Fosun Pharma (2196 HK)

317
Analysis
Health Care • China
Fosun Pharma is a global innovation-driven healthcare group with core businesses in pharmaceutical manufacturing and R&D, medical devices and diagnosis, and healthcare services. The company focuses on therapeutic areas such as oncology, immunology, and central nervous system disorders, offering products like Artesun® and Yi Kai Da. It was founded in 1994 and is headquartered in Shanghai, China.
more
•09 Jul 2015 06:01

Who's Optimistic About Pharmacy's Future in China? China Nepstar's Controlling Shareholder

China Nepstar's Chairman and his China Neptunus Drugstore Holding Ltd. (54% owner) has offered $2.60/ADS to take the company private (announcement...

Share
•01 Jul 2015 22:01

China ADR Privatizations: The Challenges of Getting the Best Deal

The stellar performance of China’s stock markets over the past twelve months (Shanghai +121%, Shenzhen +161%, and Hong Kong +17%) has led to a...

Share
•21 Feb 2015 00:02

Opening of E-commerce Channel to Change China's Drug Market

Numerous press outlets report that China’s Food & Drug Administration (CFDA) will release regulations permitting online sales of...

Share
•05 Feb 2015 16:01

Introducing Long Term Leaders - Focussed Insights for your Core Holdings

We are pleased to announce the roll out of our latest content vertical: Long Term Leaders. Under this category,  we have identified companies that...

Logo
497 Views
Share
bullish•Insilico Medicine
•06 Mar 2026 16:48

InSilico Medicine (ISM HK): Firing on Both Cylinders

Insilico Medicine announced that ISM4808, an AI-driven potential best-in-class oral drug candidate for CKD-related anemia previously out-licensed...

Logo
250 Views
Share
x